KCM
TVTX icon

Kennedy Capital Management’s Travere Therapeutics TVTX Stock Holding History

Kennedy Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-249,569
Closed -$5.61M – 697
2023
Q1 		$5.61M Sell
249,569
-33,774
-12% -$718K 0.17% 231
2022
Q4 		$5.96M Buy
283,343
+117,114
+70% +$2.48M 0.17% 210
2022
Q3 		$4.1M Buy
+166,229
New +$4.29M 0.12% 301

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Kennedy Capital Management's TVTX Position: Q2 2023 in Review

Kennedy Capital Management sold out of Travere Therapeutics (TVTX) in Q2 2023, closing a stake of 249,569 shares — an estimated $5.61M sold.

Kennedy Capital Management first reported a position in TVTX in Q3 2022 and held it in 3 quarters. The position peaked at $5.96M in Q4 2022. 169 funds tracked by Wall St. Rank hold TVTX as of Q2 2023.

  • Kennedy Capital Management reported no remaining Travere Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Kennedy Capital Management sold 249,569 Travere Therapeutics shares in Q2 2023, an estimated $5.61M.
  • Kennedy Capital Management first reported a position in Travere Therapeutics in Q3 2022 and held it in 3 quarters.
  • Kennedy Capital Management's Travere Therapeutics position peaked at $5.96M in Q4 2022.
  • 169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2023.

Based on Kennedy Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.